Capecitabine and Oxaliplatin in Treating Patients With Metastatic Breast Cancer

OUTLINE: This is a multi-center study. CAPOX (21 day cycle): * Capecitabine 825 mg/m2 orally twice daily Days 1-14. * Oxaliplatin 100 mg/m2 intravenously Day 1 Patients may continue combination therapy until progression or toxicity intervenes. Patients who discontinue either agent due to toxicity may, at the investigators discretion, continue therapy with the remaining single agent on study. ECOG performance status 0 or 1 Hematopoietic:· * ANC \> 1,200/mm3· * Platelets \> 100,000/mm3 Hepatic:· * Total bilirubin \< 1.5 x ULN· * AST \< 2 x ULN (up to 5 x ULN in patients with known liver involvement) Renal:· * Serum creatinine \< 1.5 x ULN and estimated creatinine clearance \>50ml/min as calculated with Cockroft-Gault equation Cardiovascular:· * No clinically significant cardiac disease (e.g. congestive heart failure, symptomatic coronary artery disease and cardiac arrhythmias not well controlled with medication) or myocardial infarction within the last 12 months.